BIOCOMPATIBLE, ARTIFICIAL ARTERY FOR CORONARY BYPASS GRAFT SURGERY

Advancing CABG Procedures by Eliminating Vessel Harvesting

A Medical Technology Gamechanger

Your Cells. Your Vessel. Your Recovery.

Our MAVERICS graft is a small, flexible tube encased in a nitinol scaffold that replaces the need for blood vessel harvesting in heart bypass surgery patients, creating a more efficient, cost-effective, and drastically less invasive procedure.

#1

18M

2B

1M

Cause of Death Worldwide

Annual Heart
Disease Deaths

Annual Bypass Surgeries Performed Worldwide

Adults At Risk
For Heart Disease

The CABG Challenge

INVASIVE VEIN HARVESTING PROCEDURES FOR CORONARY ARTERY BYPASS GRAFT PATIENTS PRESENT PAINFUL COMPLICATIONS:

  • Minimally invasive treatments for cardiac blockages, such as stents, can be helpful in some cases, but bypass surgery is the preferred option when more than two arteries are involved.

  • Bypass surgery is typically the method that provides more complete revascularization.

  • Each bypass surgery requires the surgical team to create additional incisions to harvest vessels from a patient’s arms or legs to use in the bypass procedure, which can lead to significant post-op complications, pain, and a host of related issues for a patient and their care team.

FOR OVER 60 YEARS, RESEARCHERS HAVE TRIED TO DEVELOP AN ARTIFICIAL GRAFT UNSUCCESSFULLY.

BLOOD VESSELS ARE DIFFICULT TO REPLICATE. A GRAFT MUST BE:

FLEXIBLE

To account for individual patient placements and the constant movements and contractions of the
circulatory system.

STRONG

The heart pumps 40 million times per year! Every beat is a lifeline, and durability ensures patients can depend on it for years of healthier living.

BIOCOMPATIBLE

So the body doesn’t create inflammation, blockages, or rejection of the graft. Reducing risks and improving outcomes motivate our innovation.

MAVERICS GRAFT

Our MAVERICS graft is a small-diameter flexible tube encased in a nitinol scaffold that eliminates the need to harvest blood vessels from the patient’s legs, arms, and chest. This leads to a higher quality of life for the patient through less pain, decreased procedure and recovery time, and lower risk of infection and complications.

An Option for Cardiac
Revascularization Procedures

MEDICAL 21 IS CHANGING EVERYTHING

  • The MAVERICS Graft is thin, flexible, and resilient enough to withstand the intense and very specific conditions the cardiovascular system requires.

  • The graft will be assimilated by the body allowing for perfusion of nutrients and cellular integration.

  • The nitinol scaffold adds arterial-like strength, flexibility, and biocompatibility.

Our Revolutionary Solution

MEDICAL 21 ELIMINATES THE NEED FOR
VESSEL HARVESTING WHICH WILL:

  • Lower Risk of Infections

  • Prevent Additional Scarring

  • Decrease Time in ICU Recovery

  • Increase Number Of Eligible Patients

  • Significantly Reduce Procedure Time

Cardiovascular Disease: A Global Issue

800K

2.5M

Annual
Bypass Surgeries

Annual
Bypass Grafts

2B

$15B

Adults At Risk
For Heart Disease

Market
Potential

A Distinguished Partner

Medical 21 was honored to be approached by The Mayo Clinic with an opportunity for collaboration. Both parties have since entered
a partnership agreement allowing The Mayo Clinic to participate
in human Medical 21 clinical trials.

Medical 21 Leadership

Meet The Team

Medical 21 Advisory Board

  • John Babbit

    Partner, Life Sciences at Ernst & Young

    Read Bio

  • Robert Emery Jr., M.D.

    Cardiac Surgeon (Retired)

    Read Bio

  • David Joyce, M.D.

    Cardiovascular Surgeon, New Mexico Heart Institute, Lovelace Medical Center, Ardent Health

    Read Bio

  • Lyle Joyce, M.D., Ph. D.

    Cardiac Surgeon (Retired)

    Read Bio

  • Gene Myers, M.D.

    Interventional Cardiologist

    Read Bio

  • Madhavan L. Raghavan, Ph.D.

    Professor of Biomedical Engineering, Univ. of Iowa

    Read Bio
Meet Our Advisory Board